This research develops a targeted anti-VEGF therapy for wet age-related macular degeneration that can be injected under the skin rather than directly into the eye. In animal studies, the drug successfully reached the eye and reduced abnormal blood vessel growth, offering a safer, cheaper, and more convenient treatment for preventing blindness.

This research develops a hybrid drug for dry age-related macular degeneration, combining anti-inflammatory and antioxidant mechanisms. By targeting both inflammation and oxidative stress, it aims to slow disease progression more effectively than existing treatments. Laboratory models test whether the combined therapy outperforms individual or co-administered components in preserving retinal function.